Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMARD discontinuation in rheumatoid arthritis patients on TNF inhibitors
NL-OMON61228Phase 4Recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methotrexate and leflunomide in rheumatoid arthritis (RA) (2 arms), sponsored by Sint Maartenskliniek. Primary endpoint: Between-group difference in mean time-weighted DAS28-CRP over 24 months. Started Jun 2026; status: recruiting.
02
Drugs
methotrexateleflunomide
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON61228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61228.